Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial.
Ann Oncol
; 26(12): 2429-36, 2015 Dec.
Article
in En
| MEDLINE
| ID: mdl-26387142
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Breast Neoplasms
/
Antineoplastic Combined Chemotherapy Protocols
/
Receptor, ErbB-2
/
Neoadjuvant Therapy
/
Antibodies, Monoclonal
Type of study:
Clinical_trials
/
Prognostic_studies
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Middle aged
Language:
En
Journal:
Ann Oncol
Journal subject:
NEOPLASIAS
Year:
2015
Document type:
Article
Affiliation country:
Italia
Country of publication:
Reino Unido